Chronic Obstructive Pulmonary Disease (COPD) is the fourth leading cause of death worldwide and represents one of the major causes of chronic morbidity. Cigarette smoking is the most important risk factor for COPD. In these patients, the airflow limitation is caused by a mixture of small airways disease and parenchyma destruction, the relative contribution of which varies from person to person. The twofold nature of the pathology has been studied in the past and according to some authors each patient should be classified as presenting a predominantly bronchial or emphysematous phenotype. In this study we applied various explorative analysis techniques (PCA, MCA, MDS) and recent unsupervised clustering methods (KHM) to study a large dataset, acquired from 415 COPD patients, to assess the presence of hidden structures in data corresponding to the different COPD phenotypes observed in clinical practice. In order to validate our methods, we compared the results obtained from a training set of 415 patients with lung density data acquired in a test set of 93 patients who underwent HRCT (High Resolution Computerized Tomography).

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jbi.2009.05.008DOI Listing

Publication Analysis

Top Keywords

analysis techniques
8
unsupervised clustering
8
clustering methods
8
chronic obstructive
8
obstructive pulmonary
8
pulmonary disease
8
disease copd
8
copd phenotypes
8
copd patients
8
copd
5

Similar Publications

Double bond (C═C) position isomerism in unsaturated lipids can indicate abnormal lipid metabolism and pathological conditions. Novel chemical derivatization and mass spectrometry-based techniques are under continuing development to provide more accurate elucidation of lipid structure in finer structural detail. Here, we introduce a new ion chemistry for annotating lipid C═C positions, which is highly efficient for liquid chromatography-mass spectrometry-based lipidomics.

View Article and Find Full Text PDF

Objective: To develop and validate a nomogram model for predicting central venous catheter-related infections (CRI) in patients with maintenance hemodialysis (MHD).

Methods: MHD patients with central venous catheters (CVCs) visiting the outpatient hemodialysis (HD) center of Xuzhou Medical University Affiliated Hospital from January 2020 to December 2023 were retrospectively selected through a HD monitoring system. Patient data were collected, and the patients were divided into training and validation sets in a 7:3 ratio.

View Article and Find Full Text PDF

Objective: Temporal encephaloceles (TEs) are seen in patients with drug-resistant epilepsy (DRE); yet they are also common incidental findings. Variability in institutional pre-surgical epilepsy practices and interpretation of epileptogenic network localization contributes to bias in existing epilepsy cohorts with TE, and therefore the relevance of TE in DRE remains controversial. We sought to estimate effect sizes and sample sizes necessary to demonstrate clinically relevant improvements in seizure outcome with different surgical approaches.

View Article and Find Full Text PDF

In the present study, a norfloxacin (NFX) fluorescent probe was tailored for the spectrofluorometric measurement of cefepime (CFP). The proposed approach measured the quenching effect of CFP on the fluorescence intensity of NFX in acetate buffer solution. The obtained results show that CFP strongly quenches the fluorescence of NFX in a static mechanism.

View Article and Find Full Text PDF

Efficacy and safety of daprodustat in patients on peritoneal dialysis in the ASCEND-D trial.

Nephrol Dial Transplant

November 2024

Department of Medicine and Nephrology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico.

Background And Hypothesis: Daprodustat, an oral hypoxia-inducible factor prolyl hydroxylase inhibitor, is approved for treatment of anemia in dialysis patients with CKD in some parts of the world. This subgroup analysis examined the efficacy and safety of daprodustat versus darbepoetin alfa in patients with anemia of CKD undergoing peritoneal dialysis (PD).

Methods: ASCEND-D (NCT02879305) was an open-label, Phase 3 trial; patients with CKD were randomized to daprodustat daily and epoetin alfa (HD patients) or darbepoetin alfa (PD patients).

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!